tbuckley/cabot-search huggingface dataset:
T Cell Receptor Specificity Is Critical for the Development of Epidermal γδ T Cells
Authors: Isabel Ferrero, Anne Wilson, Friedrich Beermann, Werner Held, H. Robson MacDonald
Journal: The Journal of Experimental Medicine (2001)

A particular feature of γδ T cell biology is that cells expressing T cell receptor (TCR) using specific Vγ/Vδ segments are localized in distinct epithelial sites, e.g., in mouse epidermis nearly all γδ T cells express Vγ3/Vδ1. These cells, referred to as dendritic epidermal T cells (DETC) originate from fetal Vγ3+ thymocytes. The role of γδ TCR specificity in DETC's migration/localization to the skin has remained controversial. To address this issue we have generated transgenic (Tg) mice expressing a TCR δ chain (Vδ6.3-Dδ1-Dδ2-Jδ1-Cδ), which can pair with Vγ3 in fetal thymocytes but is not normally expressed by DETC. In wild-type (wt) Vδ6.3Tg mice DETC were present and virtually all of them express Vδ6.3. However, DETC were absent in TCR-δ−/− Vδ6.3Tg mice, despite the fact that Vδ6.3Tg γδ T cells were present in normal numbers in other lymphoid and nonlymphoid tissues. In wt Vδ6.3Tg mice, a high proportion of in-frame Vδ1 transcripts were found in DETC, suggesting that the expression of an endogenous TCR-δ (most probably Vδ1) was required for the development of Vδ6.3+ epidermal γδ T cells. Collectively our data demonstrate that TCR specificity is essential for the development of γδ T cells in the epidermis. Moreover, they show that the TCR-δ locus is not allelically excluded.
Predictors of Graft Patency 3 Years After Coronary Artery Bypass Graft Surgery fn1fn1This research was supported by the Cooperative Studies Program of the Medical Research Service, Department of Veterans Affairs Central Office, Washington, D.C.
Authors: Steven Goldman, Karen Zadina, Barbara Krasnicka, Thomas Moritz, Gulshan Sethi, Jack Copeland, Theron Ovitt, William Henderson
Journal: Journal of the American College of Cardiology (1997)
ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up
Authors: N. Colombo, C. Creutzberg, F. Amant, T. Bosse, A. González-Martín, J. Ledermann, C. Marth, R. Nout, D. Querleu, M.R. Mirza, C. Sessa, M. Abal, O. Altundag, F. Amant, Antoni van Leeuwenhoek, S. Banerjee, T. Bosse, A. Casado, L.C. de Agustín, D. Cibula, N. Colombo, C. Creutzberg, J.-M. del Campo, G. Emons, F. Goffin, A. González-Martín, S. Greggi, C. Haie-Meder, D. Katsaros, V. Kesic, C. Kurzeder, S. Lax, F. Lécuru, J. Ledermann, T. Levy, D. Lorusso, J. Mäenpää, C. Marth, X. Matias-Guiu, P. Morice, H.W. Nijman, R. Nout, M. Powell, D. Querleu, M.R. Mirza, N. Reed, A. Rodolakis, H. Salvesen, J. Sehouli, C. Sessa, A. Taylor, A. Westermann, A.G. Zeimet
Journal: Annals of Oncology (2015)
Alternative membrane forms of Fc gamma RIII(CD16) on human natural killer cells and neutrophils. Cell type-specific expression of two genes that differ in single nucleotide substitutions.
Authors: J V Ravetch, B Perussia
Journal: The Journal of Experimental Medicine (1989)

A low affinity receptor for IgG immune complexes, Fc gamma RIII(CD16), is expressed on human NK cells as an integral membrane glycoprotein anchored through a transmembrane peptide; on polymorphonuclear neutrophils (PMN) the receptor is anchored through a phosphatidylinositol (PI) linkage. The protein on NK cells has a molecular mass 6-10 kD larger than that on PMN, and, unlike the latter, is resistant to PI-specific phospholipase C (PI-PLC). Fc gamma RIII(CD16) transcripts isolated from PMN and NK cells of single donors revealed multiple single nucleotide differences, one of which converts an in frame UGA termination codon to a CGA codon. The resulting open reading frame encodes a longer cytoplasmic domain for Fc gamma RIII(CD16) in NK cells, contributing to its transmembrane anchor. Two nearly identical, linked genes that encode these transcripts have been cloned for Fc gamma RIII(CD16), one of which (III-1) is allelic for NA-1 and NA-2. The allelic sites have been mapped to two single nucleotides in the extracellular domain. These genes are transcribed in a cell type-specific fashion to generate the alternatively anchored forms of this receptor.
Use of CD137 up-regulation to identify T cell receptors specifically reactive with mutated tumor associated antigens from tumor infiltrating lymphocytes
Authors: Maria Parkhurst, Alena Gros, Pasetto Anna, Eric Tran, Jessica S Crystal, Todd Prickett, Paul Robbins, Steven A Rosenberg
Journal: Journal for ImmunoTherapy of Cancer (2015)

Meeting abstracts The adoptive transfer of tumor infiltrating lymphocytes (TIL) can mediate the regression of metastatic melanoma. In addition, the adoptive transfer of lymphocytes genetically modified to express tumor reactive T cell receptors (TCRs) can mediate tumor regression. Many T cells from
Combi-D: Quality of Life (Qol) Impact of the Combination of Dabrafenib and Trametinib (D + T) Versus Dabrafenib Monotherapy (D) in Patients with Braf V600E/K Unresectable or Metastatic Melanoma in a Phase III Trial
Authors: D. Schadendorf, M.M. Amonkar, D. Stroyakovskiy, E. Levchenko, H. Gogas, F.G.M. De Braud, J.-. Grob, I. Bondarenko, C. Garbe, C. Lebbe, J. Larkin, V. Chiarion-Sileni, M. Millward, A. Arance, M. Mandalà, M. Casey, D.J. Demarini, J. Irani, G. Aktan, G.V. Long
Journal: Annals of Oncology (2014)
Body size and risk of kidney stones.
Authors: G C Curhan, W C Willett, E B Rimm, F E Speizer, M J Stampfer
Journal: Journal of the American Society of Nephrology (1998)

A variety of factors influence the formation of calcium oxalate kidney stones, including gender, diet, and urinary excretion of calcium, oxalate, and uric acid. Several of these factors may be related to body size. Because men on average have a larger body size and a threefold higher lifetime risk of stone formation than women, body size may be an important risk factor for calcium oxalate stone formation. The association between body size (height, weight, and body mass index) and the risk of kidney stone formation was studied in two large cohorts: the Nurses' Health Study (NHS; n = 89,376 women) and the Health Professionals Follow-up Study (HPFS; n = 51,529 men). Information on body size, kidney stone formation, and other exposures of interest was obtained by mailed questionnaires. A total of 1078 incident cases of kidney stones in NHS during 14 yr of follow-up and a total of 956 cases in HPFS during 8 yr of follow-up were confirmed. In both cohorts, the prevalence of a stone disease history and the incidence of stone disease were directly associated with weight and body mass index. However, the magnitude of the associations was consistently greater among women. Specifically, the age-adjusted prevalence odds ratio for women with body mass index > or = 32 kg/m2 compared with 21 to 22.9 kg/m2 was 1.76 (95% confidence interval, 1.50 to 2.07), but 1.38 (95% confidence interval, 1.16 to 1.65) for the same comparison in men. For incident stone formation, the multivariate relative risks for the similar comparisons were 1.89 (1.51 to 2.36) for women and 1.19 (0.83 to 1.70) in men. Height was inversely associated with the prevalence of stone disease but was not associated with incident stone formation. These results suggest that body size is associated with the risk of stone formation and that the magnitude of risk varies by gender. Additional studies are necessary to determine whether a reduction in body weight decreases the risk of stone formation, particularly in women.
Hypertrophic Cardiomyopathy in Children, Adolescents, and Young Adults Associated With Low Cardiovascular Mortality With Contemporary Management Strategies
Authors: Barry J. Maron, Ethan J. Rowin, Susan A. Casey, John R. Lesser, Ross F. Garberich, Deepa M. McGriff, Martin S. Maron
Journal: Circulation (2015)

Background— Youthful age has been considered the time of greatest risk for patients with hypertrophic cardiomyopathy (HCM), largely because of the possibility of sudden death. The last 2 decades have witnessed more reliable identification of at-risk patients and utilization of implantable cardioverter-defibrillators for prevention of sudden death, and other contemporary treatment options. Whether such management advances have significantly altered the considerable mortality rate for young HCM patients remains unresolved. Methods and Results— We studied long-term outcome in 474 consecutive HCM patients between 7 and 29 years of age presenting at 2 referral institutions. Over 7.1±5.1 years of follow-up (6.0 [3.0, 10.0]), 452 patients (95%) survived, with 95% experiencing no or mild symptoms. HCM-related death occurred in 18 patients (3%; 0.54%/y): arrhythmic sudden death (n=12), progressive heart failure and heart transplant complications (n=5), or postoperatively (n=1). In contrast, aborted life-threatening events occurred in 63 other high-risk patients (13%) with implantable cardioverter-defibrillator interventions for ventricular tachyarrhythmias (n=31), resuscitated out-of-hospital cardiac arrest (n=20), or heart transplant for advanced heart failure (n=12), 1.8%/y, 3-fold higher than HCM mortality. Five- and 10-year survival (considering only HCM deaths) was high (97% and 94%, respectively), virtually identical to that reported in middle-aged adult HCM patients (98% and 94%, P =0.23). Conclusions— In a large hospital-based cohort of young HCM patients, representing an age group considered at greatest risk, low mortality rates can be achieved with the application of contemporary cardiovascular treatment strategies, largely because of reliable identification of high-risk patients who benefited from implantable cardioverter-defibrillators for sudden death prevention, thereby creating the opportunity for extended longevity and good quality of life.
CA-125: an evolving role in the management of ovarian cancer.
Authors: M Markman
Journal: Journal of Clinical Oncology (1996)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1996.14.5.1411 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 8622053 CA-125: an evolving role in the management of ovarian cancer. M MarkmanxM MarkmanSearch for articles by this author https://doi.org/10.1200/JCO.1996.14.5.1411 PDF "CA-125: an evolving role in the management of ovarian cancer.." Journal of Clinical Oncology, 14(5), pp. 1411–1412© 1996 by American Society of Clinical Oncology
Bioequivalence study of abacavir/lamivudine (600/300-mg) tablets in healthy Thai volunteers under fasting conditions
Authors: Ekawan Yoosakul, Jaturavit Vattanarongkup, Chutima Manamuti, Bancha Chuasuwan, Isariya Techatanawat, Busarat Karachot, Porranee Puranajoti
Journal: Asian Journal of Pharmaceutical Sciences (2015)
Inhibition of T cell proliferation by human alveolar macrophages
Authors: J. M GRANGE;, P. G HOLT, J. W UPHAM
Journal: Thorax (1998)

The demonstration by Upham et al 1that human alveolar macrophages selectively inhibit proliferation of T cells by secretion of unidentified effector molecules raises the question as to whether pathological processes in the lung characterised by extensive macrophage recruitment or activation can have a systemic effect on T cell development.

It has been shown in several studies that patients with pulmonary tuberculosis who are not infected by HIV often show a lymphopenia principally affecting the CD4+ T cells.2 3 This appears to be a transient phenomenon as the CD4+ …
Cardiac arrhythmias during central venous catheter procedures in acute renal failure
Authors: E Fiaccadori, G Gonzi, P Zambrelli, G Tortorella
Journal: Journal of the American Society of Nephrology (1996)

To define the frequency and risk factors of cardiac arrhythmias during central venous catheter procedures in acute renal failure, continuous electrocardiographic monitoring with permanent recording was performed before and during 201 guidewire insertions in 171 patients requiring a central venous catheter for parenteral nutrition and/or dialysis access (121 procedures in 107 patients with acute renal failure; 39 procedures in 31 patients with normal renal function; 41 procedures in 33 patients with ESRD on chronic hemodialysis). No differences in cardiac arrhythmia frequencies were found during baseline recording. New arrhythmias were documented in 85 cases (85/201; 42%) during the catheter procedure. Ventricular arrhythmia frequencies increased significantly in all groups, as compared with baseline values (P < 0.05 for the control group, P < 0.01 for the chronic hemodialysis group, P < 0.001 for the acute renal failure group); the most noteworthy increase was observed in the acute renal failure group. Statistically significant differences among frequencies of total ventricular arrhythmias, advanced ventricular arrhythmias, and ventricular tachycardia during central venous catheter procedures were found between the acute renal failure group and both the normal renal function group (P < 0.05 to P < 0.001), and the chronic hemodialysis group (P < 0.05 to P < 0.01). All arrhythmias resolved spontaneously soon after partial guidewire withdrawal; nine episodes were symptomatic (in one case, ventricular tachycardia, followed by 10 s asystolia); no death directly related to the catheter procedure was observed. BUN and serum creatinine levels, as well as guidewire length remaining inside the patient, were significantly higher (P < 0.01) in patients with cardiac arrhythmias during central venous catheter procedures as compared with patients without arrhythmias; differences in other variables known as possible risk factors for arrhythmias (anatomical position, preexistent cardiac disease, utilization of proarrhythmogenic drugs, hypoxemia, acid-base status, and serum electrolytes, etc.) were not significant. Our study suggests that (1) patients with acute renal failure are at increased risk for cardiac arrhythmias during central venous catheter procedures; (2) an important risk factor is also represented by guidewire overinsertion, a technical error that should be avoided.
Response to Open Peer Commentaries on “Looking for Trouble: Preventive Genomic Sequencing in the General Population and the Role of Patient Choice”
Authors: Gabriel Lázaro-Muñoz, John M. Conley, Arlene M. Davis, Marcia Van Riper, Rebecca L. Walker, Eric T. Juengst
Journal: The American Journal of Bioethics (2015)

Preventive genomic sequencing (PGS) programs aimed at the general adult population hold much promise for improving human health. However, there are numerous unanswered questions about whether and h...
Observations on Chronic Polyarthritis in Monkeys
Authors: E G L Bywaters
Journal: Journal of the Royal Society of Medicine (1981)

Erosion and inflammatory changes in the carpus, fingers and toes of a rhesus monkey, Macaca mulatta, are described; this was one of 152 animals in each of which four fixed limbs were available for examination. The histological changes resembled closely those found in adult human rheumatoid arthritis. The limited literature is reviewed (including cases with amyloid disease).
A shared idiotype among human anti-Ro/SSA autoantibodies.
Authors: K K Gaither, J B Harley
Journal: The Journal of Experimental Medicine (1989)

Idiotypes and antiidiotypes are thought to be important immune regulators and have provided clues for the origin and pathogenicity of autoantibodies. Many lupus and Sjögren's syndrome patients, as well as most neonatal lupus infants with congenital heart block or dermatitis, have antibodies to the ribonucleoprotein Ro/SSA, which is one of a group of RNA-protein autoantigens commonly found in human lupus sera. To characterize the fine specificity of anti-Ro/SSA antibodies, a rabbit antidiotypic serum was prepared against polyclonal affinity purified anti-Ro/SSA F(ab')2. The resulting antiidiotype, anti-Id-Rol, is specific for the F(ab')2 fraction of the anti-Ro/SSA immunogen and its binding to anti-Ro/SSA is inhibited by purified Ro/SSA. These data indicate that the Id-Rol epitope on anti-Ro/SSA is associated with the antigen binding site of these same antibodies. The Id-Rol idiotype was present by ELISA in 3 of 12 additional anti-Ro/SSA preparations from precipitin-positive donor sera and in anti-Ro/SSA from one normal donor with low level antibody. This is the first shared idiotype to be found in the human autoantibodies binding to this RNA-protein antigen. Idiotypic differences between anti-Ro/SSA autoantibodies have the potential to explain the variation in pathologic associations found in individuals who develop this autoantibody specificity.
Do anorectics get well? Current research and future needs
Authors: D M Schwartz, M G Thompson
Journal: American Journal of Psychiatry (1981)

The authors review data from 12 major outcome studies of anorexia nervosa published in the 15 years since the last review article of Ziolko (1966). Across the 12 studies the mortality rate from self-starvation was 6%. On follow-up, well over half of the subjects continued to have eating difficulties, and close to half showed other signs of psychiatric impairment. In nonsymptomatic areas of adjustment there was a striking contrast between the 90% who were successfully employed and the 54% who made some minimal form of marital or social adjustment. The authors present a series of recommendations about the form and content of future research in the field.
Interferon and IL-27 antagonize the function of group 2 innate lymphoid cells and type 2 innate immune responses
Authors: Kazuyo Moro, Hiroki Kabata, Masanobu Tanabe, Satoshi Koga, Natsuki Takeno, Miho Mochizuki, Koichi Fukunaga, Koichiro Asano, Tomoko Betsuyaku, Shigeo Koyasu
Journal: Nature Immunology (2015)
Growth hormone in renal transplantation--the mode of action, animal studies, and clinical use.
Authors: O Mehls, B Tönshoff
Journal: Journal of the American Society of Nephrology (1992)

During circulation, growth hormone (GH) is bound to about 50% by the high-affinity, low-capacity GH-binding protein (BP). GHBP represents the extracellular binding domain of the GH receptor and modulates the action of GH. After binding to its receptor, GH induces the local production of insulin-like growth factor 1 (IGF-1) by autocrine and paracrine mechanisms. In uremia, the plasma GH-binding activity is low and does not get up-regulated by recombinant human GH treatment, which is in contrast to the experience in short, normal children. There is evidence that hepatic IGF-1 production is low, whereas the serum concentration of IGF-binding protein 3 (IGF-BP3) and other IGFBPs is increased because of the reduced renal clearance of the low-molecular-weight fragment of IGF-BP. This result in the reduced bioavailability of free IGF-1 and reduced IGF bioactivity. There is a strong interaction between GH and corticosteroids. Corticosteroids suppress growth by reducing the food efficiency ratio (weight gain per food intake), reduce pituitary GH secretion, and decrease the local production of and cell responsiveness for IGF-1. The growth-depressing and catabolic effects of corticosteroids can be counterbalanced dose dependently by recombinant human GH in animal experiments, and growth can be improved in corticosteroid-treated renal allograft recipients with and without normal renal function. It is not clear at this time to what extent GH may induce acute or chronic rejection crises.
How comparable are rates of malignancies in patients with rheumatoid arthritis across the world? A comparison of cancer rates, and means to optimise their comparability, in five RA registries
Authors: Johan Askling, Niklas Berglind, Stefan Franzen, Thomas Frisell, Christopher Garwood, Jeffrey D Greenberg, Meilien Ho, Marie Holmqvist, Laura Horne, Eisuke Inoue, Kaleb Michaud, Fredrik Nyberg, Dimitrios A Pappas, George Reed, Eiichi Tanaka, Trung N Tran, Suzanne M M Verstappen, Hisashi Yamanaka, Eveline Wesby-van Swaay, Deborah Symmons
Journal: Annals of the Rheumatic Diseases (2015)

The overall incidence of cancer in patients with rheumatoid arthritis (RA) is modestly elevated. The extent to which cancer rates in RA vary across clinical cohorts and patient subsets, as defined by disease activity or treatment is less known but critical for understanding the safety of existing and new antirheumatic therapies. We investigated comparability of, and means to harmonise, malignancy rates in five RA registries from four continents.Participating RA registries were Consortium of Rheumatology Researchers of North America (CORRONA) (USA), Swedish Rheumatology Quality of Care Register (SRR) (Sweden), Norfolk Arthritis Register (NOAR) (UK), CORRONA International (several countries) and Institute of Rheumatology, Rheumatoid Arthritis (IORRA) (Japan). Within each registry, we analysed a main cohort of all patients with RA from January 2000 to last available data, and sensitivity analyses of sub-cohorts defined by disease activity, treatment change, prior comorbidities and restricted by calendar time or follow-up, respectively. Malignancy rates with 95% CIs were estimated, and standardised for age and sex, based on the distributions from a typical RA clinical trial programme population (fostamatinib).There was a high consistency in rates for overall malignancy excluding non-melanoma skin cancer (NMSC), for malignant lymphomas, but not for all skin cancers, across registries, in particular following age/sex standardisation. Standardised rates of overall malignancy excluding NMSC varied from 0.56 to 0.87 per 100 person-years. Within each registry, rates were generally consistent across sensitivity analyses, which differed little from the main analysis.In real-world RA populations, rates of both overall malignancy and of lymphomas are consistent.
Pneumococcal vaccine for HIV patients
Authors: P. McDonald, L. Lighton, R. Anderson
Journal: BMJ (1995)

Patients with HIV infection should be immunised…

EDITOR,--We were dismayed by the article of A Jain and colleagues, which was published just as we were about to start a pneumococcal vaccine campaign in Tameside. We do not agree with the conclusions of Jain and colleagues, and we do not see how they arrived at them from the evidence they cite.

We agree that the Department of Health's policy …
Reduction of Microalbuminuria in Patients With Type 2 Diabetes
Authors: Takashi Uzu, Makoto Sawaguchi, Hiroshi Maegawa, Atsunori Kashiwagi
Journal: Diabetes Care (2007)

Reduction of microalbuminuria in patients with type 2 diabetes mellitus: the Shiga Microalbuminuria Reduction Trial (SMART) Received for publication 8 December 2006 and accepted in revised form 2 March 2007. Takashi Uzu, Makoto Sawaguchi, Hiroshi Maegawa, Atsunori Kashiwagi, for the Shiga Microalbuminuria Reduction Trial (SMART) group*